Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Diagnostic device sits at the center of this dementia and brain health question.
Diagnostic device companies are racing to meet stringent new FDA standards for Alzheimer’s blood tests after regulatory changes fundamentally transformed how these tests are developed, validated, and approved. Starting in July 2024, the FDA ruled that laboratory-developed tests for Alzheimer’s must comply with the same rigorous standards as medical devices, including quality benchmarks, performance validation across different populations, and mandatory adverse event reporting. This shift from largely unregulated tests to FDA-supervised diagnostics represents one of the most significant changes in Alzheimer’s testing in recent years, forcing companies like Fujirebio, Roche, Quest Diagnostics, and others to restructure their operations and prove their tests actually work as claimed.
The stakes are high. Misdiagnosis in Alzheimer’s can lead patients and their families down the wrong treatment path, delay access to proven therapies, or trigger unnecessary anxiety. For decades, blood-based biomarker tests operated in a regulatory gray zone—available commercially but largely unapproved by the FDA. Now, companies must demonstrate that their tests meet specific sensitivity and specificity thresholds by 2028, a deadline that has already forced some significant changes in how Alzheimer’s diagnostics are offered to patients.
Table of Contents
- What Are the New FDA Standards for Alzheimer’s Diagnostic Tests?
- FDA-Cleared Blood Tests That Have Already Met the Standards
- Clinical Practice Guidelines and Performance Thresholds
- What This Means for Patients and Healthcare Providers
- The Challenge of Test Variability and Population Differences
- How Diagnostic Companies Are Responding to the New Requirements
- What’s Next for Alzheimer’s Diagnostics
- Conclusion
What Are the New FDA Standards for Alzheimer’s Diagnostic Tests?
The FDA’s May 2024 ruling established concrete performance requirements that diagnostic companies must meet. Tests must achieve a minimum of 90 percent sensitivity and 75 percent specificity to serve as a triaging test, and even higher accuracy—90 percent in both sensitivity and specificity—to potentially replace more invasive methods like amyloid positron emission tomography (PET) imaging or spinal fluid testing. These aren’t arbitrary numbers; they reflect the clinical consensus on what constitutes a reliable diagnostic tool in dementia care. The compliance timeline is phased: companies have until July 2028 to ensure their tests meet these minimum standards and have been validated across diverse patient populations, including different ages, races, and genetic backgrounds.
Beyond accuracy requirements, the new standards also mandate quality controls and adverse event reporting. Companies must document how they perform quality checks on their tests, maintain appropriate records, and report any safety issues to the FDA. This mirrors the oversight applied to traditional medical devices like MRI machines or blood pressure monitors—a major shift from the largely self-regulated landscape that existed before. The four-year timeline was intentionally generous, giving companies time to conduct large-scale studies and make necessary modifications without abruptly pulling tests off the market.
FDA-Cleared Blood Tests That Have Already Met the Standards
The first real-world success came in May 2025, when the FDA cleared Fujirebio’s Lumipulse test for Alzheimer’s diagnosis. The Lumipulse showed greater than 91 percent agreement with brain amyloid imaging scans, exceeding the FDA’s performance thresholds. This wasn’t a breakthrough in isolation—amyloid biomarker blood tests had been in clinical use for years. But having FDA clearance meant Fujirebio had submitted their data, undergone formal FDA review, and proven that their manufacturing and quality controls met federal standards. For patients and clinicians, FDA clearance provides a third-party verification that the test works as advertised.
In October 2025, Roche’s Elecsys pTau181 received FDA clearance with a specific clinical advantage: it became the first blood test approved for primary care use to rule out Alzheimer’s-related amyloid pathology. This distinction matters because it expanded where these tests could be used. Instead of requiring a specialist’s office or memory clinic, patients could potentially discuss the test with their family doctor. However, even approved tests have limitations. Roche’s test is designed to help rule out Alzheimer’s pathology in people with cognitive concerns, not to diagnose Alzheimer’s disease definitively on its own—a subtle but important distinction that clinicians need to understand when counseling patients.
Clinical Practice Guidelines and Performance Thresholds
In July 2025, the Alzheimer’s Association released the first formal clinical practice guideline specifically for blood-based biomarkers, translating the FDA’s regulatory requirements into actionable standards for doctors. The guideline established two tiers: tests meeting 90 percent sensitivity and 75 percent specificity can be used for triaging—helping identify which patients warrant further evaluation with advanced imaging or cognitive testing. Tests achieving 90 percent sensitivity and 90 percent specificity can potentially replace amyloid PET imaging or cerebrospinal fluid testing, eliminating the need for more invasive or expensive procedures. This distinction has important implications for cost and accessibility. A patient in a rural area might previously have traveled hours to reach a PET imaging center.
With an approved blood test, a local lab or physician office might be able to perform the same diagnostic function more quickly and cheaply. Yet a critical limitation emerged: many commercially available tests do not meet these thresholds. Even among the tests companies have been offering for years, significant variability exists. Some tests performed well in research studies but haven’t yet undergone the formal validation required to confirm their accuracy across broader, more diverse patient populations. Patients considering these tests should ask their doctor specifically whether the test they’re considering has FDA clearance or, at minimum, clinical validation data that meets the Alzheimer’s Association guidelines.
What This Means for Patients and Healthcare Providers
For patients with memory concerns, the new standards theoretically make diagnosis easier and more accessible. Instead of jumping directly to expensive PET scans or invasive lumbar punctures to check cerebrospinal fluid, a patient can start with a simple blood draw. If the blood test is negative for Alzheimer’s pathology (according to an FDA-approved test), it helps reassure both patient and doctor that Alzheimer’s disease is unlikely and other causes of cognitive symptoms should be explored. If the test is positive, it indicates further evaluation is warranted—perhaps with cognitive testing or imaging to stage the disease and discuss treatment options.
However, patients and clinicians face a complicated landscape during this transition period. Some tests carry FDA clearance, some have strong clinical validation without FDA clearance, and some are still being used despite having neither. A patient might order a blood test through their doctor and feel confident in the result, only to later learn that the specific test used hasn’t met the new FDA standards. Healthcare systems and individual practices are navigating this differently—some have already switched to FDA-cleared tests, while others continue using established tests that haven’t yet pursued FDA approval but have decent published accuracy data. The safest approach for patients is to ask their healthcare provider directly: Is this test FDA-cleared? If not, what data supports its accuracy, and how will these results be used in my care plan?.
The Challenge of Test Variability and Population Differences
The requirement to validate tests across different populations—varying by age, race, ethnicity, and genetic background—addresses a longstanding problem in medical diagnostics: many tests perform differently depending on who they’re tested in. An Alzheimer’s blood test that was validated primarily in older white patients might not perform the same way in younger people, Asian populations, or populations with different genetic backgrounds. The FDA’s insistence on this broader validation is appropriate, but it also slows down the timeline for companies trying to earn clearance. Some companies have the resources to conduct large, diverse clinical studies; others do not.
This economic reality creates a tier system where larger, well-funded companies like Roche and Fujirebio can more readily jump through the new regulatory hoops, while smaller diagnostic companies or academic medical centers offering in-house tests may struggle. This concentration of approved tests among larger manufacturers could reduce choice in the market and potentially affect pricing. Additionally, some existing tests will never pursue FDA clearance—either because the companies lack resources, the business case isn’t compelling, or the tests weren’t developed with formal regulatory approval as the goal. These tests may still be used clinically for years, creating confusion about which tests are truly validated and which rely more on clinical reputation than rigorous data.
How Diagnostic Companies Are Responding to the New Requirements
Fujirebio and Roche are the clear leaders in gaining FDA clearance, having invested in the validation studies and regulatory navigation required to earn approval. Other companies like Quest Diagnostics, LabCorp, ALZPath, and C2N Diagnostics are offering blood-based biomarker tests but operate in a more ambiguous space—some with strong published accuracy data but without formal FDA clearance as of now. Large laboratory networks like Quest and LabCorp have the infrastructure and clinical reach to potentially pursue FDA clearance for their tests, while smaller companies may adapt by partnering with larger labs or focusing on specific niches.
Quest Diagnostics, for example, offers several Alzheimer’s biomarker panels through their own testing infrastructure, reaching millions of patients annually through their laboratory network. But whether these tests will all pursue or achieve FDA clearance remains to be seen. Some companies may decide it’s more economically rational to phase out tests that don’t meet the new thresholds rather than invest millions in validation studies. This could actually improve the overall quality of testing available—eliminating mediocre tests and strengthening the reputation of those that pass the FDA’s scrutiny.
What’s Next for Alzheimer’s Diagnostics
Looking ahead, the FDA’s regulatory changes will likely accelerate innovation in some directions while potentially slowing it in others. Companies with FDA-cleared tests now have a competitive advantage and market differentiation, which could incentivize other manufacturers to pursue clearance. Within the next few years, patients should see more FDA-approved blood tests for Alzheimer’s and related conditions, and clinical guidelines will become clearer about which tests are appropriate for which situations. By 2028, when the compliance deadline arrives, the landscape should be much more standardized and transparent.
The broader implication is that Alzheimer’s diagnostics are maturing as a field. Moving from a largely unregulated landscape to FDA oversight mirrors what happened in other areas of medicine decades ago. The transition period is messy—confusion about which tests are validated, variable availability depending on where patients live and who they see, and costs that may shift as the market consolidates around approved tests. But the end result should be that patients with memory concerns have reliable, accurate blood tests available in their communities, enabling faster diagnosis and quicker access to treatments like monoclonal antibodies that can slow cognitive decline in early Alzheimer’s disease.
Conclusion
Diagnostic device companies have no choice but to adapt to the FDA’s new standards for Alzheimer’s blood tests. The standards are now clear: tests must achieve 90 percent sensitivity and 75 percent specificity minimum, be validated across diverse populations, and comply with quality and reporting requirements by 2028. Companies like Fujirebio and Roche have already cleared this bar, offering patients and clinicians FDA-approved options. But during this transition, confusion remains about which tests are validated, which are approved, and which should be considered experimental or outdated.
For anyone concerned about memory loss or cognitive decline, the practical next step is to speak with a neurologist, geriatrician, or primary care doctor about Alzheimer’s blood testing. Ask specifically whether the test being proposed is FDA-cleared and what the results would mean for your diagnosis and treatment. The new standards exist to protect you—ensuring that diagnostic tests actually work as claimed. As more tests earn FDA approval and clinical practice guidelines become clearer, accessing reliable, accurate Alzheimer’s diagnostics should become faster, easier, and more equitable across communities.
You Might Also Like
- New Molecular Target Found for Blocking Alzheimer’s Cell Death
- Why the Public Health Response to Dementia Should Mirror the Coordinated Approach Used for Heart Disease Prevention
- Why Maintaining Social Connections Through Technology Could Be Key to Dementia Prevention for Homebound Seniors
For more, see National Institute on Aging.
